RxDoctor Payments DataLook up a doctor →

Joan Quinn, MD

Family Medicine · Elkhorn, NENPI 1104938786

Payments from drug & device makers

$10,920in general payments, 2019–2025

Across 766 payments — averaging $14.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$908
  • AstraZeneca$429
  • plus $4K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)182$2,287
Amgen(2 entities)91$1,366
Novo Nordisk81$1,198
Lilly USA, LLC100$1,111
Pfizer81$908
AstraZeneca15$429
Axsome Therapeutics, Inc.13$367
Otsuka America Pharmaceutical, Inc.14$303
Johnson & Johnson17$285
Takeda Pharmaceuticals U.S.A., Inc.19$242
Merck14$204
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$185
Astellas Pharma US Inc7$154
Currax Pharmaceuticals LLC17$153
Biohaven Pharmaceutical Holding Company Ltd.9$148
Sanofi Pasteur Inc.6$110
Exact Sciences5$85
Bayer5$77
Sanofi-aventis U.S. LLC5$77
Upsher-smith Laboratories LLC4$67
Biohaven Pharmaceuticals, Inc.3$66
Abbott3$66
Amarin Pharma, Inc.4$65
Medtronic3$61
Kowa Pharmaceuticals America, Inc.4$54
Gilead3$53
Eisai Inc.3$48
Inspire Medical Systems, Inc.2$45
Kyowa Kirin, Inc.3$43
Scilex Pharmaceuticals Inc.2$41
Organon3$40
Idorsia Pharmaceuticals US Inc2$38
Boehringer Ingelheim3$38
Bristol Myers Squibb2$37
Impel Pharmaceuticals Inc.2$37
Daiichi Sankyo Inc.2$31
Dermira, Inc.2$31
Actelion Pharmaceuticals US, Inc.2$29
GSK2$29
Ultragenyx Pharmaceutical Inc.2$29
Nalpropion Pharmaceuticals LLC2$29
Xeris Pharmaceuticals, Inc.1$22
Supernus Pharmaceuticals, Inc.1$21
Genentech USA, Inc.1$20
Boston Scientific1$20
Corium, LLC1$19
Arbor Pharmaceuticals, Inc.1$18
Corcept Therapeutics1$17
Esperion Therapeutics, Inc.1$16
E.r. Squibb & Sons, L.L.C.1$16
Dexcom, Inc.1$15
Jazz Pharmaceuticals Inc.1$14
Teva Pharmaceuticals USA, Inc.1$14
Regeneron Healthcare Solutions, Inc.1$13
Acadia Pharmaceuticals Inc1$12
Shire North American Group Inc1$11
Sumitomo Pharma America, Inc.1$6

How this compares

$10,920 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024
$104,580
Medicare patients
177
Services billed
2,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Elkhorn

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →